MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.55
-0.24
-0.64%
After Hours: 37.72 +0.17 +0.46% 16:11 01/17 EST
OPEN
38.13
PREV CLOSE
37.79
HIGH
38.73
LOW
37.14
VOLUME
168.18K
TURNOVER
--
52 WEEK HIGH
46.33
52 WEEK LOW
27.75
MARKET CAP
2.13B
P/E (TTM)
63.45
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XNCR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XNCR News

  • Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
  • Zacks.01/09 22:10
  • How Xencor, Inc. (NASDAQ:XNCR) Can Impact Your Portfolio Volatility
  • Simply Wall St..01/08 17:08
  • Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
  • Business Wire.01/08 13:01
  • Company News For Dec 30, 2019
  • Zacks.12/30/2019 15:13

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About XNCR

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
More

Webull offers Xencor Inc (XNCR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.